Corcept Therapeutics Incorporated’s CORT share price has dipped by 19.51%, which has investors questioning if this is right time to buy.

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...